In humans, the treatment with calcitriol in CKD patients promotes beneficial effects on the kidneys unrelated to PTH and mineral metabolism, including activity of renin-angiotensin-aldosterone system suppression, reduction of proteinuria, reduction of podocyte loss associated with glomerular hypertrophy and antiproliferative and antifibrotic effects [114,115,116,117]. This evidence concerns the gene PTH and chronic kidney disease.